- Medera’s Sardocor Announces FDA Clearance of IND for First-in-Human Gene Therapy Clinical Trial for DMD Cardiomyopathy
- Medera’s Sardocor Announces FDA Clearance of Investigational New Drug Application and Initiation of First-In-Human Gene Therapy Clinical Trial for Heart Failure with Preserved Ejection Fraction (HFpEF)
- Medera’s Novoheart partners with AstraZeneca on First Bioengineered Human Models of Heart Failure with Preserved Ejection Fraction
- 3D-printed mini-organs may provide safe testing of COVID-19 therapies
- Novoheart Named 2020 Venture 50 Company Ranked Among Year’s Top Performing Stocks in Life Sciences
No comments to show.